Human Papillomavirus (HPV) Genotyping Panels Market Report 2026

Human Papillomavirus (HPV) Genotyping Panels Market Overview

• Human Papillomavirus (HPV) Genotyping Panels market size has reached to $1.79 billion in 2025 • Expected to grow to $2.07 billion in 2030 at a compound annual growth rate (CAGR) of 3% • Growth Driver: Rising Prevalence Of HPV-related Cancers Fueling The Growth Of The Market Due To Increasing Need For Early Detection And Targeted Screening • Market Trend: Innovations In HPV Detection Through Self-Collected Sample Testing • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Human Papillomavirus (HPV) Genotyping Panels Market?

Human papillomavirus (HPV) genotyping panels are standardized diagnostic assay systems designed to identify and differentiate multiple HPV genotypes within a single biological sample by analyzing their unique genetic signatures. These panels enable simultaneous detection of a broad spectrum of HPV types, including those associated with varying levels of clinical risk, through multiplexed analysis of viral DNA. The main product types of Human Papillomavirus (HPV) genotyping panels include high-risk Human Papillomavirus (HPV) genotyping panels, low-risk Human Papillomavirus (HPV) genotyping panels, and comprehensive Human Papillomavirus (HPV) genotyping panels. High-risk HPV genotyping panels refer to molecular diagnostic assays used to detect oncogenic HPV strains associated with cervical cancer and other HPV-related diseases, enabling early diagnosis and risk stratification. They are based on technologies including polymerase chain reaction (PCR)-based, deoxyribonucleic acid (DNA) microarray, next-generation sequencing, and hybridization methods. They are used across applications such as clinical diagnostics, research, epidemiological studies, and others and they are utilized by end users including hospitals and clinics, diagnostic laboratories, research institutes, and others.

What Is The Human Papillomavirus (HPV) Genotyping Panels Market Growth Forecast?

The human papillomavirus (HPV) genotyping panels market size is expected to see steady growth in the next few years. It will grow to $2.07 billion in 2030 at a compound annual growth rate (CAGR) of 3.0%. The growth in the forecast period can be attributed to rising demand for personalized and precision diagnostics, increasing adoption of next generation sequencing technologies, expanding use of Ai enabled diagnostic interpretation systems, growing focus on early cancer detection and preventive healthcare, increasing investment in advanced molecular diagnostic platforms. Major trends in the forecast period include increasing adoption of next generation sequencing based HPV genotyping platforms, growing use of multiplex PCR assays for high throughput viral detection, rising demand for comprehensive cervical cancer screening solutions, expanding integration of digital pathology and molecular diagnostics, increasing shift toward automated and high sensitivity diagnostic workflows.

Global Human Papillomavirus (HPV) Genotyping Panels Market Segmentation

1) By Product Type: High-Risk Human Papillomavirus (HPV) Genotyping Panels, Low-Risk Human Papillomavirus (HPV) Genotyping Panels, Comprehensive Human Papillomavirus (HPV) Genotyping Panels 2) By Technology: Polymerase Chain Reaction (PCR)-Based, Deoxyribonucleic Acid (DNA) Microarray, Next-Generation Sequencing, Hybridization 3) By Application: Clinical Diagnostics, Research, Epidemiological Studies, Other Applications 4) By End-User: Hospitals And Clinics, Diagnostic Laboratories, Research Institutes, Other End-Users Subsegments: 1) By High-Risk Human Papillomavirus (HPV) Genotyping Panels: Human Papillomavirus (HPV) 16 Genotyping Panels, Human Papillomavirus (HPV) 18 Genotyping Panels, Extended High-Risk Human Papillomavirus (HPV) Panel, E6 Or E7 Oncogene-Specific Genotyping Panels 2) By Low-Risk Human Papillomavirus (HPV) Genotyping Panels: Human Papillomavirus (HPV) 6 Genotyping Panels, Human Papillomavirus (HPV) 11 Genotyping Panels, Cutaneous Low-Risk Human Papillomavirus (HPV) Panels, Genital Wart-Associated Human Papillomavirus (HPV) Panels, Multi-Type Low-Risk Human Papillomavirus (HPV) Panels 3) By Comprehensive Human Papillomavirus (HPV) Genotyping Panels: Combined High-Risk And Low-Risk Human Papillomavirus (HPV) Panels, Full Spectrum Human Papillomavirus (HPV) Panels, Deoxyribonucleic Acid (DNA) Microarray-Based Human Papillomavirus (HPV) Genotyping Panels, Next-Generation Sequencing (NGS)-Based Human Papillomavirus (HPV) Panels, Multiplex Real-Time Polymerase Chain Reaction (PCR ) Comprehensive Panels

What Are The Drivers Of The Human Papillomavirus (HPV) Genotyping Panels Market?

The rising prevalence of HPV-related cancers is expected to propel the growth of the human papillomavirus (HPV) genotyping panels market going forward. HPV-related cancers refer to malignancies caused by persistent infection with high-risk human papillomavirus strains, including cervical cancer, oropharyngeal cancer, anal cancer, vulvar cancer, and penile cancer. The prevalence of HPV-related cancers is rising due to increasing rates of HPV infection globally and growing aging populations with higher cancer susceptibility. HPV genotyping panels support the management of rising HPV-related cancer prevalence by accurately identifying specific high-risk HPV strains, enabling early diagnosis, guiding targeted treatment decisions, and facilitating population-based cervical cancer screening programs. For instance, in 2025, according to the National Institutes of Health, a US-based government agency, globally, cervical cancer accounted for an estimated 662,044 new cases and 348,709 deaths in 2022, and these figures are projected to rise significantly, with cases increasing by 56.8% and deaths by 80.7% by 2050. Therefore, the rising prevalence of HPV-related cancers is driving the growth of the human papillomavirus (HPV) genotyping panels industry. The rising healthcare expenditure is expected to propel the growth of the human papillomavirus (HPV) genotyping panels market going forward. Healthcare expenditure refers to the total spending on health services, including preventive care, diagnostic services, treatments, and healthcare infrastructure. The rise in healthcare expenditure is increasing due to expanding access to healthcare services and growing government investments in public health systems. HPV genotyping panels benefit from rising healthcare expenditure by enabling healthcare providers to invest in advanced molecular diagnostic tools, expand screening programs, improve laboratory infrastructure, and enhance early detection and management of HPV-related diseases. For instance, in April 2025, according to the American Medical Association, a US-based professional association, in 2023, health spending in the U.S. rose by 7.5%, reaching $4.9 trillion, or $14,570 per person, marking a notable increase compared to the 4.6% growth recorded in 2022. Therefore, the rising healthcare expenditure is driving the growth of the human papillomavirus (HPV) genotyping panels industry.

Key Players In The Global Human Papillomavirus (HPV) Genotyping Panels Market

Major companies operating in the human papillomavirus (hpv) genotyping panels market are F. Hoffmann-La Roche Ltd., Abbott Laboratories, Thermo Fisher Scientific Inc., Danaher Corporation, Becton Dickinson and Company, Hologic Inc., Revvity Inc., QIAGEN N.V., DiaSorin S.p.A., BGI Group, Seegene Inc., Fujirebio, Daan Gene Co. Ltd., Sansure Biotech Inc., Hybribio Limited, Tellgen Corporation, Mylab Discovery Solutions Pvt. Ltd., Molbio Diagnostics Pvt. Ltd., 3B BlackBio Dx Limited, Jiangsu Macro & Micro-Test Med-Tech Co. Ltd., Mikrogen Diagnostik, GeneFirst Limited.

Global Human Papillomavirus (HPV) Genotyping Panels Market Trends and Insights

Major companies operating in the human papillomavirus (HPV) genotyping panels market are focusing on developing advanced solutions, such as self-collection-based diagnostic solutions to expand screening accessibility, improve early detection rates, and enhance patient compliance in cervical cancer prevention programs. Self-collection-based diagnostic solutions refer to testing approaches that allow patients to collect their own biological samples, which are then analyzed using molecular assays for accurate detection and genotyping of HPV infections. For instance, in May 2024, F. Hoffmann-La Roche Ltd., a Switzerland-based healthcare company, received FDA approval for its cobas HPV Self-Collection Solution, which is integrated with the cobas HPV test. The solution enables the detection of 14 high-risk HPV genotypes, including HPV 16 and HPV 18, and allows patients to self-collect samples within healthcare settings. This innovation improves access to screening, particularly for underserved populations, and supports broader adoption of HPV testing in routine clinical practice.

Regional Outlook

North America was the largest region in the human papillomavirus (HPV) genotyping panels market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period.The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Human Papillomavirus (HPV) Genotyping Panels Market?

The human papillomavirus (HPV) genotyping panels market consists of sales of partial genotyping panels, isothermal amplification HPV genotyping kits, line probe assay HPV genotyping kits, and lyophilized HPV genotyping kits. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Human Papillomavirus (HPV) Genotyping Panels Market Report 2026?

The human papillomavirus (HPV) genotyping panels market research report is one of a series of new reports from The Business Research Company that provides human papillomavirus (HPV) genotyping panels market statistics, including human papillomavirus (HPV) genotyping panels industry global market size, regional shares, competitors with a human papillomavirus (HPV) genotyping panels market share, detailed human papillomavirus (HPV) genotyping panels market segments, market trends and opportunities, and any further data you may need to thrive in the human papillomavirus (HPV) genotyping panels industry. This human papillomavirus (HPV) genotyping panels market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.